Literature DB >> 16971697

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

N M Kemppainen1, S Aalto, I A Wilson, K Någren, S Helin, A Brück, V Oikonen, M Kailajärvi, M Scheinin, M Viitanen, R Parkkola, J O Rinne.   

Abstract

BACKGROUND: PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD).
OBJECTIVE: To employ voxel-based analysis method to identify brain regions with significant increases in [(11)C]PIB uptake in AD vs healthy control subjects, indicative of increased amyloid accumulation in these regions.
METHODS: We studied 17 patients with AD and 11 control subjects with PET using [(11)C]PIB as tracer. Parametric images were computed by calculating a region-to-cerebellum ratio over 60 to 90 minutes in each voxel. Group differences in [(11)C]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis.
RESULTS: SPM showed increased uptake (p < 0.001) in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate and the striatum. No significant differences in uptake were found in the primary sensory and motor cortices, primary visual cortex, thalamus, and medial temporal lobe. These results were supported by automated ROI analysis, with most prominent increases in AD subjects in the frontal cortex ([(11)C]PIB uptake 163% of the control mean) and posterior cingulate (146%) followed by the parietal (146%) and temporal (145%) cortices and striatum (133%), as well as small increases in the occipital cortex (117%) and thalamus (115%).
CONCLUSIONS: Voxel-based analysis revealed widespread distribution of increased [(11)C]PIB uptake in Alzheimer disease (AD). These findings are in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971697     DOI: 10.1212/01.wnl.0000240117.55680.0a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  88 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

3.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; John Murray; Yi Li; Lidia Glodzik; Pauline McHugh; Schantel Williams; Megan Cummings; Elizabeth Pirraglia; Stanley J Goldsmith; Shankar Vallabhajosula; Noora Scheinin; Tapio Viljanen; Kjell Någren; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2012-04-11       Impact factor: 4.673

4.  Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Authors:  Mateen C Moghbel; Babak Saboury; Sandip Basu; Scott D Metzler; Drew A Torigian; Bengt Långström; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

5.  Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; Valentina Berti; Yi Li; Huiyu Wang; John Murray; Noora Scheinin; Kjell Någren; Schantel Williams; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 6.  Amyloid positron emission tomography and cognitive reserve.

Authors:  Matteo Bauckneht; Agnese Picco; Flavio Nobili; Silvia Morbelli
Journal:  World J Radiol       Date:  2015-12-28

7.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Wen-Chun Hsu; Shiaw-Pyng Wey; Tzu-Chen Yen; Mei-Ping Kung; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

Review 8.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

9.  Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.

Authors:  Gil D Rabinovici; William J Jagust; Ansgar J Furst; Jennifer M Ogar; Caroline A Racine; Elizabeth C Mormino; James P O'Neil; Rayhan A Lal; Nina F Dronkers; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

Review 10.  Beta-amyloid deposition and the aging brain.

Authors:  Karen M Rodrigue; Kristen M Kennedy; Denise C Park
Journal:  Neuropsychol Rev       Date:  2009-11-12       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.